Aswin Abraham

Contact Overview Publications

Contact

Faculty of Medicine & Dentistry - Oncology Dept

Email: aabraham@ualberta.ca
Phone: (780) 432-8516
Address: Cross Cancer Institute
11560 University Avenue

Edmonton AB

T6G 1Z2

Overview

About

Dr. Aswin Abraham is currently appointed as Associate Professor (Special Continuing) in the Department of Oncology in the Faculty of Medicine & Dentistry.

Featured Publications

Genomic risk model to implement precision prostate cancer screening in clinical care: the ProGRESS study

NATURE CANCER. 2026 January; 10.1038/S43018-025-01103-0

Combining External Beam Radiotherapy and Immunotherapy for the Treatment of Hepatocellular Carcinoma

CURRENT ONCOLOGY. 2026 January; 10.3390/CURRONCOL33040226

Immunotherapy and Stereotactic Body Radiation Treatment-An Overview of the Current Landscape of the Strategic Combination of Two Treatment Modalities to Achieve Better Therapeutic Outcomes

CANCERS. 2026 January; 10.3390/CANCERS18111682

Adjuvant radiotherapy alone, an effective treatment option for early-stage low- risk breast cancer in women over 50: results from a population based cohort study using a Canadian provincial database

Kurian Joseph, Ayoola Ademola, Julia Zebak, Armaan Singh, Hanxiao Zuo, Heather Warkentin, Aswin Abraham, Zsolt Gabos, Keith Tankel, Susan Chafe, Karen King

Radiotherapy and Oncology. 2025 December; 10.1016/j.radonc.2025.111175

Early Detection of Lung Cancer: A Review of Innovative Milestones and Techniques

JOURNAL OF CLINICAL MEDICINE. 2025 January; 10.3390/JCM14217812

Prevention of radiation induced cardiotoxicity in patients with left sided breast cancer: results from a phase 2 clinical trial

EUROPEAN HEART JOURNAL SUPPLEMENTS. 2025 January; 10.1093/EURHEARTJSUPP/SUAF083.084

A population-based analysis of the impact of 1 vs. 2 doses of mitomycin on patterns of failure of anal cancer patients treated with concurrent chemoradiotherapy

RADIOTHERAPY AND ONCOLOGY. 2024 January; 10.1016/J.RADONC.2024.110219

<SUP>18</SUP>F-Fluorodeoxyglucose Positron Emission Tomography Parameters can Predict Long-Term Outcome Following Trimodality Treatment for Oesophageal Cancer

CLINICAL ONCOLOGY. 2023 January; 10.1016/J.CLON.2022.11.003

Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants

NATURE GENETICS. 2023 January; 10.1038/S41588-023-01534-4

Does Loosening the Inclusion Criteria of the CROSS Trial Impact Outcomes in the Curative-Intent Trimodality Treatment of Oesophageal and Gastroesophageal Cancer Patients?

Clinical Oncology. 2022 June; 10.1016/j.clon.2022.05.011

Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score.

Prostate cancer and prostatic diseases. 2022 February; 10.1038/s41391-022-00497-7

Report from the Western Canadian Gastrointestinal Consensus Cancer Conference-Management of Total Neoadjuvant Therapy in Rectal Cancer.

Current oncology (Toronto, Ont.). 2022 February; 10.3390/curroncol29020078

Is Radiation-Induced Cardiac Toxicity Reversible? Prospective Evaluation of Patients With Breast Cancer Enrolled in a Phase 3 Randomized Controlled Trial.

International journal of radiation oncology, biology, physics. 2022 January; 10.1016/j.ijrobp.2022.01.020

Are two too many when it comes to the treatment of anal canal cancer with concurrent radiation and mitomycin C?

JOURNAL OF CLINICAL ONCOLOGY. 2022 January; 10.1200/JCO.2022.40.4_SUPPL.003

Tumor Volume Predicts for Pathologic Complete Response in Rectal Cancer Patients Treated With Neoadjuvant Chemoradiation

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. 2022 January; 10.1097/COC.0000000000000942

Concomitant Use of Proton Pump Inhibitors With Capecitabine Based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer

American Journal of Clinical Oncology. 2021 September; 10.1097/coc.0000000000000850

More Is Not Better When It Comes to Treating Rectal Cancer With Multimodal Chemoradiation Beyond the Standard Radiation Dose of 5040 cGy.

Diseases of the colon and rectum. 2021 June; 10.1097/dcr.0000000000001986

Hippocampal avoidance in prophylactic cranial irradiation for small cell lung cancer: benefits and pitfalls

Journal of Thoracic Disease. 2021 May; 10.21037/jtd-2019-rbmlc-01

TET2 drives 5hmc marking of GATA6 and epigenetically defines pancreatic ductal adenocarcinoma transcriptional subtypes.

Gastroenterology. 2021 April; 10.1053/j.gastro.2021.04.044

Recurrent radiation recall dermatitis 40 years after radiation therapy for breast cancer.

The breast journal. 2021 March; 10.1111/tbj.14212

A NOVEL COMPOSITE BIOMARKER PANEL FOR DETECTION OF EARLY STAGE NON-SMALL CELL LUNG CANCER

RADIOTHERAPY AND ONCOLOGY. 2021 January;

Adjuvant breast radiotherapy, endocrine therapy, or both after breast conserving surgery in older women with low-risk breast cancer: Results from a population-based study

RADIOTHERAPY AND ONCOLOGY. 2021 January; 10.1016/J.RADONC.2020.09.017

Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer.

British journal of cancer. 2020 October; 10.1038/s41416-020-01120-z

Dosimetric parameters predicting late small bowel toxicity in rectal cancer patients receiving neo-adjuvant chemo-radiation.

Abraham AG, Usmani N, Warkentin B, Thai J, Yun J, Ghosh S, Cheung W, Xu Y, Nijjar T, Severin D, Tankel K, Fairchild A, Joseph K

Practical radiation oncology. 2020 August; 10.1016/j.prro.2020.07.004

Translational analysis from SCALOP trial: CCL5 as a prognostic biomarker and a potentially actionable target in locally advanced pancreatic cancer (LAPC)

JOURNAL OF CLINICAL ONCOLOGY. 2020 January;

Breast Cancer Care in South India: Is Practice Concordant With National Guidelines?

Journal of global oncology. 2019 July; 10.1200/JGO.19.00052

High circulating CCL5 is associated with poor prognosis in locally advanced pancreatic cancer (LAPC): Biomarker analysis from the randomized phase II SCALOP trial

CANCER RESEARCH. 2019 January; 10.1158/1538-7445.PANCA19-B40

Cholangiocarcinoma treatment with Synchrony-based robotic radiosurgery system: Tracking options.

Journal of radiosurgery and SBRT. 2018 January;

ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer

RADIOTHERAPY AND ONCOLOGY. 2016 January; 10.1016/J.RADONC.2016.03.021

TGF-β Targets the Hippo Pathway Scaffold RASSF1A to Facilitate YAP/SMAD2 Nuclear Translocation

MOLECULAR CELL. 2016 January; 10.1016/J.MOLCEL.2016.05.012

Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT

JOURNAL OF CLINICAL INVESTIGATION. 2015 January; 10.1172/JCI80402

AKT regulates NPM dependent ARF localization and p53<SUP>mut</SUP> stability in tumors

ONCOTARGET. 2014 January; 10.18632/ONCOTARGET.2178

Menin determines K-RAS proliferative outputs in endocrine cells

JOURNAL OF CLINICAL INVESTIGATION. 2014 January; 10.1172/JCI69004

PI3K/Akt-mediated regulation of p53 in cancer

BIOCHEMICAL SOCIETY TRANSACTIONS. 2014 January; 10.1042/BST20140070

Targeting radiation resistance in p53 mutant tumors with AKT inhibitors.

JOURNAL OF CLINICAL ONCOLOGY. 2013 January;

View additional publications